4D pharma plc (LON:DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, today announced that the Annual Report and Accounts for the year to 31 December 2017 and Notice of the Company’s Annual General Meeting (“AGM”) have been posted to shareholders.
An electronic copy of each of the Annual Report and Accounts and the Notice of AGM is available on the Company’s website, www.4dpharmaplc.com.
The AGM will be held on Monday 21 May 2018 at 11 a.m. at the Gridiron Building, 1 Pancras Square, London N1C 4AG.
Founded in February 2014, 4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform that rationally identifies novel bacteria that have a precise and evolved therapeutic effect. All of 4D’s live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D has completed a phase I study in Irritable Bowel Syndrome and has recently completed dosing in a phase I study in Paediatric Crohn’s Disease. It currently has a pipeline of 13 pre-clinical programmes, covering disease areas such as cancer, poorly controlled asthma, autoimmune and CNS disease, and plans to commence four additional clinical studies in 2018.